Discriminative stimulus and reinforcing effects of p-fluoro-L-deprenyl in monkeys

Psychopharmacology

Volumn 182, Issue 1, 2005, Pages 95-103

  Yasar, Sevil ^a,b   Gaal, Jozsef ^c   Justinova, Zuzana ^b   Bergman, Jack ^d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c MegaPharma Ltd   (Hungary)

^d MCLEAN HOSPITAL   (United States)

Author keywords

Amphetamine; Cocaine; Deprenyl; Drug discrimination; Methamphetamine; p Fluoro L deprenyl; Self administration; Squirrel monkey

Indexed keywords

4 FLUORO LEVO AMPHETAMINE; 4 FLUORO LEVO DEPRENYL; 4 FLUORO LEVO METHYLAMPHETAMINE; COCAINE; METHAMPHETAMINE; SELEGILINE; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; DRUG STRUCTURE; MALE; NONHUMAN; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; REINFORCEMENT; SQUIRREL MONKEY; TIME; TRAINING;

AMPHETAMINE-RELATED DISORDERS; AMPHETAMINES; ANIMALS; ASSOCIATION LEARNING; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE; CONDITIONING, CLASSICAL; DEXTROAMPHETAMINE; DISCRIMINATION LEARNING; DOSE-RESPONSE RELATIONSHIP, DRUG; GENERALIZATION, STIMULUS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAVENOUS; METHAMPHETAMINE; MOTIVATION; REINFORCEMENT SCHEDULE; SAIMIRI; SELEGILINE; SELF ADMINISTRATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 25844481699     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-005-0063-y     Document Type: Article

References (59)

1. Amsterdam JD (2003) A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry 64:208-214
2. Ansari KS, Yu PH, Kruck TP, Tatton WG (1993) Rescue of axotomized immature rat facial motoneurons by R(-)-deprenyl: stereospecificity and independence from monoamine oxidase inhibition. J Neurosci 13:4042-4053
3. Barber AJ, Yu PH, Boulton AA (1993) Chronic effects of monoamine oxidase-B inhibitors on the behaviour of aged mice. Life Sci 53:739-747
4. Bartzokis G, Beckson M, Newton T, Mandelkern M, Mintz J, Foster JA, Ling W, Bridge TP (1999) Selegiline effects on cocaine-induced changes in medial temporal lobe metabolism and subjective ratings of euphoria. Neuropsychopharmacology 20:582-590
5. Bergman J, Yasar S, Winger G (2001) Psychomotor stimulant effects of beta-phenylethylamine in monkeys treated with MAO-B inhibitors. Psychopharmacology (Berl) 159:21-30
6. Berry MD, Juorio AV, Paterson IA (1994) Possible mechanisms of action of (-)deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders. Prog Neurobiol 44:141-161
7. Bodkin JA, Amsterdam JD (2002) Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry 159:1869-1875
8. Bodkin JA, Cohen BM, Salomon MS, Cannon SE, Zornberg GL, Cole JO (1996) Treatment of negative symptoms in schizophrenia and schizoaffective disorder by selegiline augmentation of antipsychotic medication. A pilot study examining the role of dopamine. J Nerv Ment Dis 184:295-301
9. Buu NT, Angers M (1987) Effects of different monoamine oxidase inhibitors on the metabolism of 1-dopa in the rat brain. Biochem Pharmacol 36:1731-1735
10. Carrillo MC, Kanai S, Nokubo M, Kitani K (1991) (-) deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats. Life Sci 48:517-521
11. Carrillo MC, Kanai S, Nokubo M, Ivy GO, Sato Y, Kitani K (1992) (-)Deprenyl increases activities of superoxide dismutase and catalase in striatum but not in hippocampus: the sex and age-related differences in the optimal dose in the rat. Exp Neurol 116:286-294
12. Carrillo MC, Kitani K, Kanai S, Sato Y, Miyasaka K, Ivy GO (1994) The effect of a long term (6 months) treatment with (-)deprenyl on antioxidant enzyme activities in selective brain regions in old female Fischer 344 rats. Biochem Pharmacol 47:1333-1338
13. Cohen G (1983) The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence. J Neural Transm Suppl 19:89-103
14. Dallo J, Knoll J (1992) Effect of (-)-para-fluoro-deprenyl on survival and copulation in male rats. Acta Physiol Hung 79:125-129
15. Di Ciano P, Everitt BJ (2003) Differential control over drug-seeking behavior by drug-associated conditioned reinforcers and discriminative stimuli predictive of drug availability. Behav Neurosci 117:952-960
16. Erdo F, Baranyi A, Takacs J, Aranyi P (2000) Different neurorescue profiles of selegiline and p-fluoro-selegiline in gerbils. NeuroReport 11:2597-2600
17. Freedman M, Rewilak D, Xerri T, Cohen S, Gordon AS, Shandling M, Logan AG (1998) L-Deprenyl in Alzheimer's disease: cognitive and behavioral effects. Neurology 50:660-668
18. Fuller RW, Hemrick-Luecke SK (1982) Influence of ring and side chain substituents on the selectivity of amphetamine as a monoamine oxidase inhibitor. Res Commun Subst Abuse 3:159
19. Fuller RW, Baker JC, Perry KW, Molloy BB (1975) Comparison of 4-chloro-, 4-bromo- and 4-fluoroamphetamine in rats: drug levels in brain and effects on brain serotonin metabolism. Neuropharmacology 14:739-746
20. Gelowitz DL, Paterson IA (1999) Neuronal sparing and behavioral effects of the antiapoptotic drug, (-)deprenyl, following kainic acid administration. Pharmacol Biochem Behav 62:255-262
21. Gibson CJ (1987) Inhibition of MAO B, but not MAO A, blocks DSP-4 toxicity on central NE neurons. Eur J Pharmacol 141:135-138
22. Goldberg SR (1973) Comparable behavior maintained under fixed-ratio and second-order schedules of food presentation, cocaine injection or d-amphetamine injection in the squirrel monkey. J Pharmacol Exp Ther 186:18-30
23. Goldberg SR, Kelleher RT, Morse WH (1975) Second-order schedules of drug injection. Fed Proc 34:1771-1776
24. Goldberg SR, Spealman RD, Kelleher RT (1979) Enhancement of drug-seeking behavior by environmental stimuli associated with cocaine or morphine injections. Neuropharmacology 18:1015-1017
25. Grabowski J, Shearer J, Merrill J, Negus SS (2004) Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addict Behav 29:1439-1464
26. Harvey JA, McMaster SE, Fuller RW (1977) Comparison between the neurotoxic and serotonin-depleting effects of various halogenated derivatives of amphetamine in the rat. J Pharmacol Exp Ther 202:581-589
27. Heikkila RE, Hess A, Duvoisin RC (1984) Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 224:1451-1453
28. Heinonen EH, Savijarvi M, Kotila M, Hajba A, Scheinin M (1993) Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease. J Neural Transm Parkinson's Dis Dement Sect 5:193-202
29. Houtsmuller EJ, Thornton JA, Stitzer ML (2002) Effects of selegiline (L-deprenyl) during smoking and short-term abstinence. Psychopharmacology (Berl) 163:213-220
30. Knoll J (1988) The striatal dopamine dependency of life span in male rats. Longevity study with (-)deprenyl. Mech Ageing Dev 46:237-262
31. Knoll J, Magyar K (1972) Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 5:393-408
32. Knoll J, Toth V, Kummert M, Sugar J (1992) (-)deprenyl and (-)parafluorodeprenyl-treatment prevents age-related pigment changes in the substantia nigra. A TV-image analysis of neuromelanin. Mech Ageing Dev 63:157-163
33. Lajtha A, Sershen H, Cooper T, Hashim A, Gaal J (1996) Metabolism of (-)-deprenyl and PF-(-)-deprenyl in brain after central and peripheral administration. Neurochem Res 21:1155-1160
34. Lane EL, Cheetham S, Jenner P (2005) Dopamine uptake inhibitor-induced rotation in 6-hydroxydopamine-lesioned rats involves both D1 and D2 receptors but is modulated through 5-hydroxytryptamine and noradrenaline receptors. J Pharmacol Exp Ther 312:1124-1131
35. Langston JW, Irwin I, Langston EB, Forno LS (1984) Pargyline prevents MPTP-induced parkinsonism in primates. Science 225:1480-1482
36. Magyar K (1994) Behaviour of (-)-deprenyl and its analogues. J Neural Transm Suppl 41:167-175
37. Magyar K (1997) Effect of selegiline against selective neurotoxins. Vopr Med Khim 43:504-514
38. Magyar K, Knoll J (1975) para-Substituted amphetamines and brain serotonin. Pol J Pharmacol Pharm 27:139-143
39. Marona-Lewicka D, Rhee GS, Sprague JE, Nichols DE (1995) Psychostimulant-like effects of p-fluoroamphetamine in the rat. Eur J Pharmacol 287:105-113
40. McMahon LR, Cunningham KA (2001) Role of 5-HT(2a) and 5-HT (2B/2C) receptors in the behavioral interactions between serotonin and catecholamine reuptake inhibitors. Neuropsychopharmacology 24:319-329
41. Negus SS, Mello NK (2003) Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a second-order schedule in rhesus monkeys. Drug Alcohol Depend 70:39-52
42. Newton TF, Kalechstein A, Beckson M, Bartzokis G, Bridge TP, Ling W (1999) Effects of selegiline pretreatment on response to experimental cocaine administration. Psychiatry Res 87:101-106
43. Panlilio LV, Yasar S, Nemeth-Coslett R, Katz JL, Henningfield JE, Solinas M, Heishman SJ, Schindler CW, Goldberg SR (2005) Human cocaine-seeking behavior and its control by drug-associated stimuli in the laboratory. Neuropsychopharmacology 30:433-443
44. Paterson IA, Barber AJ, Gelowitz DL, Voll C (1997) (-)Deprenyl reduces delayed neuronal death of hippocampal pyramidal cells. Neurosci Biobehav Rev 21:181-186
45. Ritz MC, Kuhar MJ (1989) Relationship between self-administration of amphetamine and monoamine receptors in brain: comparison with cocaine. J Pharmacol Exp Ther 248:1010-1017
46. Salo PT, Tatton WG (1992) Deprenyl reduces the death of motoneurons caused by axotomy. J Neurosci Res 31:394-400
47. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 336:1216-1222
48. Schindler CW, Panlilio LV, Goldberg SR (2002) Second-order schedules of drug self-administration in animals. Psychopharmacology (Berl) 163:327-344
49. Sloviter RS, Connor JD, Damiano BP, Drust EG (1980) para-Halogenated phenethylamines: similar serotonergic effects in rats by different mechanisms. Pharmacol Biochem Behav 13:283-286
50. Tariot PN, Goldstein B, Podgorski CA, Cox C, Frambes N (1998) Short-term administration of selegiline for mild-to-moderate dementia of the Alzheimer's type. Am J Geriatr Psychiatry 6:145-154
51. Tatton WG, Greenwood CE (1991) Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res 30:666-672
52. Tatton WG, Wadia JS, Ju WY, Chalmers-Redman RM, Tatton NA (1996) (-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. J Neural Transm Suppl 48:45-59
53. Terleckyj IA, Heikkila RE (1992) In vivo and in vitro pharmacologic profile of two new irreversible MAO-B inhibitors: MDL 72,974A and fluorodeprenyl. Ann NY Acad Sci 648:365-367
54. Tidey JW, Bergman J (1998) Drug discrimination in methamphetamine-trained monkeys: agonist and antagonist effects of dopaminergic drugs. J Pharmacol Exp Ther 285:1163-1174
55. Winger G (1994) Dopamine antagonist effects on behavior maintained by cocaine and alfentanil in rhesus monkeys. Behav Pharmacol 5:141-152
56. Winger GD, Yasar S, Negus SS, Goldberg SR (1994) Intravenous self-administration studies with 1-deprenyl (selegiline) in monkeys. Clin Pharmacol Ther 56:774-780
57. Yasar S, Bergman J (1994) Amphetamine-like effect of 1-deprenyl (selegiline) in drug discrimination studies. Clin Pharmacol Ther 56:768-773
58. Yasar S, Goldberg SR (2000) The antiparkinsonian agent selegiline (1-Deprenyl) maintains moderate rates of i.v. self-administration responding under second-order schedules in squirrel monkeys but does not attenuate the reinforcing effects of amphetamine. J Psychopharmacol 14:A20
59. Yasar S, Gaal J, Panlilio LV, Justinova Z, Redhi G, Schindler CW (under review) A comparison of drug-seeking behavior maintained by d-amphetamine, 1-deprenyl (selegiline) and d-deprenyl under a second-order schedule in squirrel monkeys, submitted to Psychopharmacology (Berl)